Abstract
In a market believed to approach 5 million people in the leading pharma
markets, the market for rheumatic anti-inflammatory drugs is both profitable
and set to increase due to new launches. The annual revenue to Q3 2006, from
the main prescription anti-inflammatory drugs worldwide, including non
steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid
combinations and specific anti-rheumatics was in the order of $16bn worldwide.
This market cannot be ignored. A life-long disease with no cure, the disease
has been targeted greatly by pharma companies with the launch of novel
targeted biologic therapies. However this has meant that the market for severe
RA has become crowded - but is it saturated?
Historically management of RA has relied on symptomatic treatment with a
variety of anti-inflammatories, toxic immunosuppressants and corticosteroids.
None of these treatments, however, had the ability to prevent underlying
disease progression. The advent of a series of new biological monoclonal
antibodies to treat RA has changed this situation dramatically. There is now a
real possibility of actually modifying the progression of chronic disease,
decreasing disability levels and enabling more normal lifestyles for RA
patients.
These new monoclonal antibodies specifically target the early pathways of
inflammation preventing damage and abrogating the onset of the vicious cycle
of inflammation and tissue destruction. The first new biological drugs for RA
are already on the market and have met with outstanding clinical success.
There are now several important regulatory issues concerning the older
biological drugs as patents are expiring and the biosimilar race by generic
companies gets underway. There is also a strong pipeline of new drugs in
development which could make exciting and important breakthroughs.
Questions however remain, that this new report will answer for you, such as:
Will the current monoclonal blockbuster used to treat RA continue to grow?
How dark is the future for coxibs and as a drug class are they doomed? What
are the hottest research drugs in the pipeline? Will the manufacture and
marketing of biosimilars overcome regulatory hurdles?
The main treatment categories discussed in the report include:
- nonsteroidal anti-inflammatories (NSAIDs, COX inhibitors known as coxibs)
- corticosteroids
- viscosupplements (for joints) - Synvisc and Suvenyl
- new biologicals (anti-TNF), Kineret ( anti IL-1Ra )
- MabThera/Rituxan (anti-CD 20), Orencia (anti-IL-2 and IL-4)
With new expensive biological drugs targeted at the US, Europe and Japan,
generating revenues of $9450m in the last 12 months, visiongain believe that
the growth of the disease within developing nations will see cheaper
alternatives increase revenue also.
With global market analysis and forecast right through to 2012, the report
tackles a SWOT breakdown affecting the use of NSAIDs and biologicals. Targeted
immunology relating to RA and sets out the targets for future research. This
is taken up in the pipelines chapter which deals with the pipeline. These two
chapters have been designed to allow the reader to get a good summary of what
is opening up in the future treatment for RA. Visiongain sees a continuing
shift towards biological treatment of RA and the treatment options are
expanding. Biologicals provide greater opportunity to modulate disease
progression and alleviate the chronic cycle of inflammation and pathology.
Leading biological companies have strong pipelines and time will determine the
future potential of the next generation of anti-inflammatory drugs. In the
meantime, the use of traditional mainstay drugs will continue until newer
agents have a proven record of safety and efficacy. The early signs with the
novel therapies look very promising.
- Exclusive information of market shares and revenues till 2012 for all of the
major drugs have been forecast -
Included in this report:
This report includes an up-to-date, analysis of RA including the current
market and possible future developments. The following important issues are
covered in detail:
- An introduction of the concepts behind AI disease
- Discussion of the immunology of RA and key issues in inflammation
- World prevalence rates and aetiological considerations
- A market analysis of the leading anti-inflammatories for RA, 2005-2006
- A market forecast for the global RA prescription market, 2007-2012
- Summaries of forecasts for the leading biological monoclonal antibodies
for RA
- SWOT analyses
- An appraisal of pipeline biologicals for RA
Methodology
The information contained in this report is from primary industry sources.
This includes one-on-one interviews with companies, with governmental bodies
and academic institutions. Analysis has also been drawn from company reports,
whether annual financial returns or white papers. The author of this report
has dealt with over 50+ companies and industry contacts to assist on the
production of this report.
Unique benefits to you when you order this report
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using
hard-drive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
View Cart
